Abstract
In China, intravenous belimumab is listed for the treatment of SLE1; however, no evaluation of its cost-effectiveness exists. We estimated the cost-effectiveness of belimumab plus standard therapy (ST) versus ST alone, among patients with SLE, from the government payer perspective in China.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
